High Telehealth Utilization Could Cancel Out Cost Savings, CBO Says

The increased utilization of health care services enabled by widespread adoption of telehealth could cancel out some of the cost savings that competition from virtual care could bring to the health care system moving forward, the Congressional Budget Office says in a policy paper laying out potential ways to reduce commercial insurers’ costs. Titled “Policy Approaches to Reduce What Commercial Insurers Pay for Hospitals’ and Physicians’ Services,” the report released Thursday (Sept. 29) details policies that could drive down costs...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

Stakeholders: GAO View That Telehealth Additive Based On ‘Ancient’ Data

Telehealth stakeholders are balking at congressional investigators’ assertion last week that telehealth’s use and cost to the health care system are likely to go up because some telehealth is additive rather than a substitute for in-person care, saying the Government Accountability Office’s findings are based on outdated data from 2017 and don’t reflect newer research showing telehealth replaced in-person care during the pandemic. Convincing lawmakers that extending pandemic telehealth flexibilities would cut overall health care costs is a major hurdle...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 




Amylyx Exec: PHOENIX Trial ‘Not A Formal Commitment’ For Relyvrio Approval

Correction: An earlier version of this story stated that Amylyx “softened” its promise to withdraw Relyvrio if the clinical trial PHOENIX fails. A company spokesperson said Amylyx stands by its promises to pull the drug if the clinical trial fails. Weeks after an Amylyx executive promised to pull Relyvrio if a post-market clinical trial doesn’t confirm the amyotrophic lateral sclerosis drug works, the executive said conducting that clinical trial, called PHOENIX, is “not a formal commitment,” but...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 10/10/2022
IDP Volume: 
Vol. 5, No. 41
Author: 




FDA Warns COVID-19 Drug Evusheld Less Effective Against Omicron

Editor's Note: This story has been corrected to say that Evusheld is less effective against certain Omicron subvariants. The story previously stated incorrectly that Evusheld is ineffective against Omicron. FDA on Monday (Oct. 3) warned health care providers that AstraZeneca’s COVID-19 drug Evusheld, which is FDA-authorized to prevent coronavirus infections in certain patients, is less effective against strains of the Omicron variant, including BA.4/BA.5 . The agency revised its fact sheet for providers, saying providers should inform...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 10/07/2022
FDA Volume: 
Vol. 28, No. 40
Author: 


CBO Highlights Price Cap Potential To Cut Private Insurer Pay To Hospitals

The Congressional Budget Office (CBO) examined three policy approaches Congress could take to reduce the high prices private plans pay for hospital and physician services and found price caps would have the most impact, while promoting competition and price transparency also would reduce costs but to a lesser degree. Price caps could lower prices by 3% to 5% or more over the next 10 years, while competition could reduce prices by 1% to 3% over the same period, CBO found...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 10/06/2022
CMS Volume: 
Vol. 25, No. 40
HEA Issue: 
Health Exchange Alert Weekly Report - 10/05/2022
HEA Volume: 
Vol. 10, No. 40
Author: 

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.